Rovati, L C <br/><br/>
Efficacy and safety of the first-in-class imidazoline-2 receptor ligand CR4056 in pain from knee osteoarthritis and disease phenotypes: a randomized, double-blind, placebo-controlled phase 2 trial.  [electronic resource] 

 -  Osteoarthritis and cartilage  01 2020 
 - 22-30 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1522-9653 
<br/><br/><label>Standard No.: </label>10.1016/j.joca.2019.09.002  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Arthralgia--drug therapy<br/>Double-Blind Method<br/>Female<br/>Humans<br/>Imidazoles--adverse effects<br/>Male<br/>Middle Aged<br/>Osteoarthritis, Knee--drug therapy<br/>Pain Measurement<br/>Proof of Concept Study<br/>Quinazolines--adverse effects<br/>Treatment Outcome